Replies to post #240856 on Biotech Values

[DewDiligence]

ABUS—This dual-nuc trial was announced back in June (#msg-164648753), so it took six months to dose the first patient. I continue to question the merit of using two nucs and think that ABUS is flailing.

[DewDiligence]

The ABUS-Antios HBV trial_has_been_truncated_by_ war_in Ukraine; from ABUS’ 4Q21 PR:

https://finance.yahoo.com/news/arbutus-reports-fourth-quarter-end-123000300.html

Enrollment is complete in a cohort of patients in Antios’ Phase 2a clinical trial evaluating AB-729, ATI-2173, Antios’ ASPIN, and Viread (tenofovir disoproxil fumarate). With the majority of patients in this cohort enrolled in Ukraine, which is currently in a state of war, they may be lost to follow-up before completing the trial. Therefore, Arbutus and Antios may report limited data on a reduced number of patients from this clinical trial.

I didn’t think much of this trial anyhow, as noted in #msg-167124650 and #msg-167129703.